LONDON, UK I June 02, 2025 I GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for ...

New drug application submission was based on positive data from the Phase III GLISTEN trial, which demonstrated significant ...

GlaxoSmithKline (GSK – Research Report) received a Hold rating and a $41.00 price target from Berenberg Bank analyst Kerry Holford today. Confident Investing Starts Here: Easily ...

GSK plc GSK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval of its ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis ...

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ...

US FDA accepts for review GSK’s NDA for linerixibat to treat cholestatic pruritus in patients with PBC: London, UK Tuesday, June 3, 2025, 11:00 Hrs [IST] GSK plc announced the U ...

And that was the Linerixibat study of an IBAT inhibitor in PBC, and we are very excited to wait to see what that data shows. In this Healio interview, Gideon Hirschfield, PhD, MB BChir ...

Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US ...

(Alliance News) - GSK PLC on Monday announced the US Food & Drug Administration has accepted for review the new drug application for its liver disease treatment, linerixibat.

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like Dupilumab, Linerixibat, and Volixibat, among others. Furthermore ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like Dupilumab, Linerixibat, and Volixibat, among others. Furthermore, the rising ...